全文获取类型
收费全文 | 389175篇 |
免费 | 25722篇 |
国内免费 | 2878篇 |
专业分类
耳鼻咽喉 | 5305篇 |
儿科学 | 8471篇 |
妇产科学 | 10796篇 |
基础医学 | 54424篇 |
口腔科学 | 12025篇 |
临床医学 | 31393篇 |
内科学 | 80455篇 |
皮肤病学 | 8754篇 |
神经病学 | 28005篇 |
特种医学 | 14222篇 |
外国民族医学 | 82篇 |
外科学 | 62160篇 |
综合类 | 10162篇 |
现状与发展 | 1篇 |
一般理论 | 72篇 |
预防医学 | 17978篇 |
眼科学 | 9798篇 |
药学 | 31789篇 |
1篇 | |
中国医学 | 2273篇 |
肿瘤学 | 29609篇 |
出版年
2021年 | 2670篇 |
2019年 | 3000篇 |
2018年 | 4898篇 |
2017年 | 3655篇 |
2016年 | 3775篇 |
2015年 | 4419篇 |
2014年 | 6173篇 |
2013年 | 8062篇 |
2012年 | 11054篇 |
2011年 | 11307篇 |
2010年 | 6875篇 |
2009年 | 6396篇 |
2008年 | 10242篇 |
2007年 | 11073篇 |
2006年 | 10962篇 |
2005年 | 10002篇 |
2004年 | 9436篇 |
2003年 | 9081篇 |
2002年 | 8694篇 |
2001年 | 28487篇 |
2000年 | 28973篇 |
1999年 | 23774篇 |
1998年 | 5101篇 |
1997年 | 4167篇 |
1996年 | 3741篇 |
1995年 | 3528篇 |
1994年 | 3147篇 |
1993年 | 2885篇 |
1992年 | 16132篇 |
1991年 | 14904篇 |
1990年 | 14213篇 |
1989年 | 14026篇 |
1988年 | 12643篇 |
1987年 | 12105篇 |
1986年 | 11141篇 |
1985年 | 10357篇 |
1984年 | 6940篇 |
1983年 | 5619篇 |
1982年 | 2736篇 |
1979年 | 5514篇 |
1978年 | 3366篇 |
1977年 | 2982篇 |
1975年 | 2651篇 |
1974年 | 3079篇 |
1973年 | 2885篇 |
1972年 | 2839篇 |
1971年 | 2786篇 |
1970年 | 2519篇 |
1969年 | 2550篇 |
1968年 | 2260篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
52.
<正>Norepinephrine (NE; also known as noradrenaline) is the body's primary adrenergic neurotransmitter which belongs to the catecholamine family. Norepinephrine has pharmacologic effects on theα1 (Suita et al.,2015),α2 (Schwartz,1997),β1,β2 andβ3(Tsukada et al., 2003) adrenoceptors. In the brain, norepinephrine increases arousal and alertness, promotes vigilance, enhances formation and retrieval of memory, and focuses attention. It also increases restlessness and anxiety. In the remainder of the body, 相似文献
53.
P.V. Chernyshov A. Lallas L. Tomas‐Aragones M. Arenbergerova M. Samimi L. Manolache A. Svensson S.E. Marron F. Sampogna S. Spillekom‐vanKoulil A. Bewley A.M. Forsea G.B. Jemec J.C. Szepietowski M. Augustin A.Y. Finlay 《Journal of the European Academy of Dermatology and Venereology》2019,33(5):816-827
The European Academy of Dermatology and Venereology (EADV) Task Forces (TFs) on Quality of Life (QoL) and Patient Oriented Outcomes, Melanoma and Non‐Melanoma Skin Cancer (NMSC) present a review of the literature and position statement on health‐related (HR) QoL assessment in skin cancer patients. A literature search was carried out to identify publications since 1980 that included information about the impact of SC on QoL. Generic, dermatology‐specific, cancer‐specific, SC‐specific, facial SC‐specific, NMSC‐specific, basal cell carcinoma‐specific and melanoma‐specific QoL questionnaires have been used to assess HRQoL in SC patients. HRQoL was assessed in the context of creation and validation of the HRQoL instruments, clinical trials, comparison of QoL in SC and other cancers, other diseases or controls, HRQoL assessment after treatment, comorbidities, behaviour modification, predictors of QoL and survival, supportive care needs, coping strategies and fear of cancer recurrence. The most widely used instruments for HRQoL assessment in SC patients are the European Organisation for Research and Treatment of Cancer Core Questionnaire (EORTC QLQ‐C30), the Functional Assessment of Cancer Therapy‐Melanoma (FACT‐M), Skin Cancer Index (SCI), Short Form 36 Item Health Survey (SF‐36) and the Dermatology Life Quality Index (DLQI). The TFs recommend the use of the cancer‐specific EORTC QLQ‐C30, especially in late stages of disease, and the melanoma‐specific FACT‐M and SC‐specific SCI questionnaires. These instruments have been well validated and used in several studies. Other HRQoL instruments, also with good basic validation, are not currently recommended because the experience of their use is too limited. Dermatology‐specific HRQoL instruments can be used to assess the impact of skin‐related problems in SC. The TFs encourage further studies to validate HRQoL instruments for use in different stages of SC, in order to allow more detailed practical recommendations on HRQoL assessment in SC. 相似文献
54.
55.
Tien‐Yao Tsai Iat‐Lon Leong Ka‐Shun Cheng Lian‐Ru Shiao Tzu‐Hui Su Kar‐Lok Wong Paul Chan Yuk‐Man Leung 《Fundamental & clinical pharmacology》2019,33(1):52-62
A pathological feature in atherosclerosis is the dysfunction and death of vascular endothelial cells (EC). Oxidized low‐density lipoprotein (LDL), known to accumulate in the atherosclerotic arterial walls, impairs endothelium‐dependent relaxation and causes EC apoptosis. A major bioactive ingredient of the oxidized LDL is lysophosphatidylcholine (LPC), which at higher concentrations causes apoptosis and necrosis in various EC. There is hitherto no report on LPC‐induced cytotoxicity in brain EC. In this work, we found that LPC caused cytosolic Ca2+ overload, mitochondrial membrane potential decrease, p38 activation, caspase 3 activation and eventually apoptotic death in mouse cerebral bEND.3 EC. In contrast to reported reactive oxygen species (ROS) generation by LPC in other EC, LPC did not trigger ROS formation in bEND.3 cells. Pharmacological inhibition of p38 alleviated LPC‐inflicted cell death. We examined whether heparin could be cytoprotective: although it could not suppress LPC‐triggered Ca2+ signal, p38 activation and mitochondrial membrane potential drop, it did suppress LPC‐induced caspase 3 activation and alleviate LPC‐inflicted cytotoxicity. Our data suggest LPC apoptotic death mechanisms in bEND.3 might involve mitochondrial membrane potential decrease and p38 activation. Heparin is protective against LPC cytotoxicity and might intervene steps between mitochondrial membrane potential drop/p38 activation and caspase 3 activation. 相似文献
56.
57.
58.
Q. Wu B. Yang S. Gao P. Gong L. Xiang Y. Man Y. Qu 《International journal of oral and maxillofacial surgery》2019,48(3):388-394
The aim of this study was to investigate a novel apical U-shape splitting technique for horizontal bone augmentation in undercut areas and to compare its efficacy with that of guided bone regeneration (GBR). This was a prospective non-randomized controlled clinical trial. A total of 36 patients, who presented with a labial undercut that was not able to house a normally inclined implant, underwent the new technique or GBR. Radiographic and clinical data were obtained preoperatively, immediately after surgery, and 12 months after surgery. Pairwise comparisons of changes in ridge width gain, marginal bone loss, and pink aesthetic score were performed; correlations with pristine ridge morphology were investigated. The results showed similar marginal bone loss in the two groups. The overall ridge width gains in the new technique group (2.56 ± 1.92 mm) and GBR group (0.73 ± 1.21 mm) differed significantly (P < 0.05). The pink aesthetic score was higher for the new technique group (11.75 ± 1.22) than for the GBR group (9.25 ± 1.86) (P < 0.01). The morphology of the concavity had different impacts on regeneration in the two groups. The apical U-shape splitting technique, as a safe and effective alternative to GBR, provided a significant increase in bone volume gain where labial fenestration was inevitable during implant placement. 相似文献
59.
D.M.L. Saunte B.M. Piraccini A.Y. Sergeev A. Prohi B. Sigurgeirsson C. Rodríguez‐Cerdeira J.C. Szepietowski J. Faergemann M. Arabatzis M. Pereiro M. Skerlev P. Lecerf P. Schmid‐Grendelmeier P. Nenoff R.J. Nowicki L. Emtestam R.J. Hay 《Journal of the European Academy of Dermatology and Venereology》2019,33(2):421-427
60.
Merkel cell carcinoma (MCC) is a rare neuroendocrine carcinoma of the skin, for which the exact mechanisms of carcinogenesis remain unknown. Therapeutic options for this highly aggressive malignancy have historically been limited in both their initial response and response durability. Recent improvements in our understanding of MCC tumor biology have expanded therapeutic options for these patients, namely through the use of immunotherapies such as immune checkpoint inhibitors. Further elucidation of the tumor mutational landscape has identified molecular targets for therapies, which have demonstrated success in other cancer types. In this review, we discuss both current and investigational immune and molecular targets of therapy for MCC. 相似文献